Home/Filings/4/0001214659-25-004545
4//SEC Filing

Horne William B. 4

Accession 0001214659-25-004545

CIK 0001677077other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 4:30 PM ET

Size

12.1 KB

Accession

0001214659-25-004545

Insider Transaction Report

Form 4
Period: 2025-03-18
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-18$0.06/sh+10,000$60016,666 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2025-03-1810,0000 total
    Exercise: $0.06Exp: 2026-04-29Common Stock (10,000 underlying)
  • Purchase

    Common Stock

    2025-03-18$0.97/sh+5,000$4,85221,666 total
Holdings
  • Stock Options (Right to Buy)

    Exercise: $225.00Exp: 2029-11-25Common Stock (1,667 underlying)
    1,667
  • Stock Options (Right to Buy)

    Exercise: $225.00Exp: 2029-11-17Common Stock (1,667 underlying)
    1,667
Footnotes (5)
  • [F1]This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options.
  • [F2]The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.9703. The range of purchase prices on the transaction date was $0.9693 to $0.9742 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
  • [F3]The stock options exercised in this transaction were fully vested and exercisable as of the transaction date.
  • [F4]The stock options vest ratably over thirty-six (36) months beginning on the date of grant and are fully vested.
  • [F5]None of these performance-based stock options are vested or exercisable.

Issuer

Alzamend Neuro, Inc.

CIK 0001677077

Entity typeother

Related Parties

1
  • filerCIK 0001333268

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:30 PM ET
Size
12.1 KB